Ryplazim FDA Approval History
Last updated by Judith Stewart, BPharm on June 16, 2021.
FDA Approved: Yes (First approved June 4, 2021)
Brand name: Ryplazim
Generic name: plasminogen, human-tvmh
Dosage form: Injection
Company: Liminal BioSciences Inc.
Treatment for: Plasminogen Deficiency Type 1
Ryplazim (plasminogen, human-tvmh) is a plasma-derived plasminogen replacement therapy for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).
- Ryplazim works by temporarily increasing plasminogen levels in the blood.
- Ryplazim is administered via intravenous infusion over 10-30 minutes every 2 to 4 days.
- Common adverse reactions include abdominal pain, bloating, nausea, fatigue, extremity pain, hemorrhage, constipation, dry mouth, headache, dizziness, arthralgia, and back pain.
Development timeline for Ryplazim
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.